Floatz logo

cgt6297

HR Positive/HER-2 Negative Breast Cancer

Cogent Biosciences, Inc.Phase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

6 Active assets in the HR Positive/HER-2 Negative Breast Cancer cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
George Washington University
Phase 2CCC
Eftilagimod Alfa
George Washington University
Phase 2CCC
Docetaxel
George Washington University
Phase 2CCC
Inno-206
George Washington University
Phase 2CCC
ntq1062
Nanjing Chia-tai Tianqing Pharmaceutical
Phase 1CC
FULVESTRANT
Nanjing Chia-tai Tianqing Pharmaceutical
Phase 1CC

Same molecule, other indications

cgt6297 is also rated in:

endometrial carcinomaDormant
C
Indicative ·
37 / 100
View asset →
PIK3CA MutationsDormant
NR
Indicative ·
/ 100
View asset →
Advanced Solid Tumors, AdultDormant
NR
Indicative ·
/ 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →